Comparison of blue dye and isotope with blue dye alone in breast sentinel node biopsy

ANZ Journal of Surgery

Volumn 75, Issue 9, 2005, Pages 817-821

  Syme, David B Y ^a   Collins, John P ^a   Mann, G Bruce ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Early breast cancer; False negative; Sentinel lymph node; Sentinel lymph node biopsy

Indexed keywords

ANTIMONY TECHNETIUM SULFIDE TC 99M; DISULFINE BLUE; DYE; EOSIN; HEMATOXYLIN; ISOTOPE; COLORING AGENT; DIAGNOSTIC AGENT; TECHNETIUM;

ADULT; AGED; ARTICLE; BREAST AREOLA; BREAST CANCER; COLLOID; DERMIS; DIAGNOSTIC ACCURACY; DRUG ADMINISTRATION; EARLY CANCER; FALSE NEGATIVE RESULT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; PERITUMORAL DRUG ADMINSTRATION; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SENTINEL NODE MAPPING; STAINING; SUBAREOLAR DRUG ADMINISTRATION; SUBDERMAL DRUG ADMINISTRATION; TECHNIQUE; TUMOR; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; BREAST NEOPLASMS; COLLOIDS; COLORING AGENTS; FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; TECHNETIUM;

EID: 33644684425     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2005.03531.x     Document Type: Article

References (22)

1. Veronesi U Paganelli G Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 2003 349: 546 53.
2. McMasters KM Tuttle TM Carlson DJ et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J. Clin. Oncol. 2000 18: 2560 6.
3. SinghRanger G Mokbel K. The evolving role of sentinel lymph node biopsy for breast cancer. Eur. J. Surg. Oncol. 2003 29: 423 5.
4. Guenther JM Hansen NM DiFronzo LA et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch. Surg. 2003 138: 52 6.
5. Giuliano AE Haigh PI Brennan MB et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J. Clin. Oncol. 2000 18: 2553 9.
6. Nos C Freneaux P Louis-Sylvestre C et al. Macroscopic quality control improves the reliability of blue dye-only sentinel lymph node biopsy in breast cancer. Ann. Surg. Oncol. 2003 10: 525 30.
7. Hill AD Tran KN Akhurst T et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann. Surg. 1999 229: 528 35.
8. Krag D. Minimal invasive staging for breast cancer: clinical experience with sentinel lymph node biopsy. Semin. Oncol. 2001 28: 229 35.
9. Mann BG Buchanan M Collins PJ Lichtenstein M. High incidence of micrometastases in breast cancer sentinel nodes. ANZ J. Surg. 2000 70: 786 90.
10. Noguchi M. Sentinel lymph node biopsy as an alternative to routine axillary lymph node dissection in breast cancer patients. J. Surg. Oncol. 2001 76: 144 56.
11. Edwards MJ Whitworth P Tafra L McMasters KM. The details of successful sentinel lymph node staging for breast cancer. Am. J. Surg. 2000 180: 257 61.
12. Ross MI. Sentinel node dissection in early-stage breast cancer: ongoing prospective randomized trials in the USA Ann. Surg. Oncol. 2001 8 ( Suppl 9 77S 81S.
13. Yong WS Wong CY Lee JS Soo KC Tan PH Goh AS. Single institution's initial experience with sentinel lymph node biopsy in breast cancer patients. ANZ J. Surg. 2003 73: 416 21.
14. Sardi A Spiegler E Colandrea J. The benefit of using two techniques for sentinel lymph node mapping in breast cancer. Am. Surg. 2002 68: 24 8.
15. Manecksha R Fey J Yeung H et al. Value of sentinel node biopsy in the management of breast cancer. Ir. J. Med. Sci. 2001 170: 233 5.
16. Meyer-Rochow GY Martin RC Harman CR. Sentinel node biopsy in breast cancer: validation study and comparison of blue dye alone with triple modality localization. ANZ J. Surg. 2003 73: 815 18.
17. Derossis AM Fey J Yeung H et al. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J. Am. Coll. Surg. 2001 193: 473 8.
18. Cody HS3rd Urban JA. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann. Surg. Oncol. 1995 2: 32 7.
19. Veronesi U Cascinelli N Greco M et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann. Surg. 1985 202: 702 7.
20. Morrow M Foster RS Jr.. Staging of breast cancer: a new rationale for internal mammary node biopsy. Arch. Surg. 1981 116: 748 51.
21. Jakub JW Diaz NM Ebert MD et al. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am. J. Surg. 2002 184: 302 6.
22. Noguchi M. Therapeutic relevance of breast cancer micrometastases in sentinel lymph nodes. Br. J. Surg. 2002 89: 1505 15.